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Abstract
Reactivation of latent Mycobacterium tuberculosis (Mtb)
infection is a major complication of anti-tumour necrosis factor
(TNF)-α treatment, but its mechanism is not fully understood.
We evaluated the effect of the TNF antagonists infliximab (Ifx),
adalimumab (Ada) and etanercept (Eta) on anti-mycobacterial
immune responses in two conditions: with ex vivo studies from
patients treated with TNF antagonists and with the in vitro
addition of TNF antagonists to cells stimulated with
mycobacterial antigens. In both cases, we analysed the
response of CD4+ T lymphocytes to purified protein derivative
(PPD) and to culture filtrate protein (CFP)-10, an antigen
restricted to Mtb. The tests performed were lymphoproliferation
and immediate production of interferon (IFN)-γ. In the 68
patients with inflammatory diseases (rheumatoid arthritis,
spondylarthropathy or Crohn's disease), including 31 patients
with a previous or latent tuberculosis (TB), 14 weeks of anti-
TNF-α treatment had no effect on the proliferation of CD4+ T
lymphocytes. In contrast, the number of IFN-γ-releasing CD4+ T
lymphocytes decreased for PPD (p < 0.005) and CFP-10 (p <
0.01) in patients with previous TB and for PPD (p < 0.05) in
Ada = adalimumab; BCG = Bacille de Calmette Guérin; CD = Crohn's disease; Cd = Candida; CFP-10 culture filtrate protein-10; CMV = cytome-
galovirus; EC50 = median effective concentration; ELISPOT = enzyme-linked immunosorbent spot; ESAT-6 = early secretory antigen target-6; Eta = 
etanercept; IFN = interferon; Ifx = infliximab; IL = interleukin; IMID = immune-mediated inflammatory disease; mAb = monoclonal antibody; Mtb = 
Mycobacterium tuberculosis; mTNF = membrane-bound tumour necrosis factor; PBMC = peripheral blood mononuclear cell; PPD = purified protein 
derivative (or tuberculin); RA = rheumatoid arthritis; SA = sponlylarthropathy; TB = tuberculosis; TNF = tumour necrosis factor; TNFR = tumour necro-
sis factor receptor; Toxo = Toxoplasma gondii; TT = Tetanus toxoid.
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other patients (all vaccinated with Bacille Calmette-Guérin).
Treatments with Ifx and with Eta affected IFN-γ release to a
similar extent. In vitro addition of TNF antagonists to CD4+ T
lymphocytes stimulated with mycobacterial antigens inhibited
their proliferation and their expression of membrane-bound TNF
(mTNF). These effects occurred late in cultures, suggesting a
direct effect of TNF antagonists on activated mTNF+ CD4+ T
lymphocytes, and Ifx and Ada were more efficient than Eta.
Therefore, TNF antagonists have a dual action on anti-
mycobacterial CD4+ T lymphocytes. Administered in vivo, they
decrease the frequency of the subpopulation of memory CD4+
T lymphocytes rapidly releasing IFN-γ upon challenge with
mycobacterial antigens. Added in vitro, they inhibit the activation
of CD4+ T lymphocytes by mycobacterial antigens. Such a dual
effect may explain the increased incidence of TB in patients
treated with TNF antagonists as well as possible differences
between TNF antagonists for the incidence and the clinical
presentation of TB reactivation.
Introduction
Tumour necrosis factor (TNF) antagonists such as the anti-
TNF monoclonal antibodies (mAbs) infliximab (Ifx) and adali-
mumab (Ada) and the soluble TNF receptor etanercept (Eta)
are efficacious in several immune-mediated inflammatory dis-
eases (IMIDs), including rheumatoid arthritis (RA), spondylar-
thropathies (SA), Crohn's disease (CD), psoriasis arthritis, and
juvenile arthritis [1-8]. However, they are also associated with
an increased incidence of infections, especially infection with
Mycobacterium tuberculosis (Mtb). Tuberculosis (TB) in
patients treated with TNF antagonists is characterised by a
high frequency of extra-pulmonary and disseminated lesions
and with few granulomas in involved organs. Because most
cases of TB develop soon after treatment initiation, they corre-
spond to a reactivation of a latent TB infection [9-11].
All three TNF antagonists have been associated with
increased incidence of TB. However, this incidence seems to
be lower for Eta than for Ifx [12,13], and the median delay
between treatment initiation and occurrence of TB was shorter
with Ifx [11]. Membrane-anchored TNF (mTNF) is expressed
by activated macrophages and T lymphocytes [14,15].
Although Ifx and Eta both neutralise soluble TNF, Ifx binds
more efficiently to mTNF than does Eta. Thus, Ifx but not Eta
induces apoptosis of activated monocytes and lamina propria
T lymphocytes from patients with CD [15,16]. The mechanism
by which TNF antagonists reactivate latent TB is not fully
understood. In animal models, TNF plays a central role in the
containment of mycobacterial infections, and T cell-derived
soluble TNF as well as mTNF are essential in protecting
against Mtb infection [17-22].
Detection of latent TB is crucial before starting treatment with
TNF antagonists because it requires a preventive treatment for
TB reactivation before TNF antagonist administration [23-25].
However, this detection is difficult, especially in individuals
vaccinated with the Bacille de Calmette Guérin (BCG). Diag-
nosis of latent TB may benefit from new in vitro assays testing
the immune response against proteins such as culture filtrate
protein (CFP)-10 and early secreted antigenic target (ESAT)-
6, which are encoded in the genome of Mtb and of a few other
mycobacterial species (Mycobacterium kansasii, Mycobacte-
rium szulgai, and Mycobacterium marinum) but not in that of
BCG and other mycobacteria. Presence of an immune
response against CFP-10 and ESAT-6 is a relatively specific
indicator of Mtb infection and has allowed for precise diagno-
sis of active as well as latent TB in several studies of BCG-vac-
cinated individuals [26-32].
In the present work, we analysed the effect of TNF antagonists
on the immune response against mycobacterial antigens,
either CFP-10 or purified protein derivative (PPD), which con-
tains antigens shared by all mycobacterial species, including
BCG. This effect was studied in two different conditions. In
patients with an active form of RA, SA, or CD, the impact of
treatment with TNF antagonists on circulating T lymphocytes
was evaluated by analyzing ex vivo their proliferation and their
rapid release of interferon (IFN)-γ in response to mycobacterial
antigens. We also determined whether TNF antagonists
added in vitro to blood cells alter their activation by mycobac-
terial antigens.
Materials and methods
Characteristics of patients
Patients were consecutively enrolled in the study between
April 2003 and May 2005. They were divided into four groups,
depending on previous or latent TB and IMID. Previous TB
was defined as a previous known history of TB with adequate
treatment. Latent TB was defined according to French recom-
mendations [23]: a previous TB with no adequate treatment, a
wheal larger than 10 mm in diameter or a blister in response to
a tuberculin skin test (TST) performed more than 10 years
after the last BCG vaccination, or radiographic evidence of
residual nodular tuberculous lesions larger than 1 cm3 in size.
Adequate treatment was a treatment initiated after 1970 and
lasting at least 6 months, including at least 2 months with the
rifampin-pyrazinamide combination [23]. Group I patients (n =
37) had RA, SA, or CD and no previous or latent TB. Group II
patients (n = 31) had RA, SA, or CD and previous or latent TB.
Group III patients (n = 21) had no RA, SA, or CD but any of
the following lung diseases: emphysema (n = 1), uninfected
chronic obstructive pulmonary disease (n = 6), asthma (n = 1),
primary arterial hypertension (n = 11), pulmonary embolism (n
= 1), or infectious pneumonitis (n = 1) with complete recovery.
They had no previous or latent TB. Group IV patients (n = 24)
had no IMID but previous TB. Twenty had been treated for TB
for a median 32 (12–52 interquartile range) years before inclu-
sion. Because BCG vaccination in infancy was mandatory in
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France until 2004, all patients in this study were expected to
be vaccinated with BCG. A specific inquiry revealed no
patients without BCG vaccination.
Patients from groups I and II were naive of TNF antagonist
treatment, and all required treatment with Ifx (RA, 3 mg/kg at
week 0, 2, 6 and then every 8 weeks; SA, 5 mg/kg with the
same schedule; CD, 5 mg/kg at week 0, 2, and 6), Ada (RA,
40 mg every other week), or Eta (RA or SA, 25 mg twice a
week). Patients from groups I and II were tested twice, at inclu-
sion and 14 weeks after initiation of anti-TNF treatment. Two
patients from group II had been previously treated for TB, 6
and 11 years before inclusion, respectively. In the other group
II patients, anti-TB treatment was initiated at least 3 weeks
before administration of the TNF antagonist and given for a
total of at least 8 weeks, according to French recommenda-
tions [23]. Anti-tuberculous treatment consisted of isoniazid +
rifampin for 3 months, isoniazid alone for 9 months, or isoniazid
+ pyrazinamide for 3 months. Patients gave informed consent,
and this study was reviewed and approved by the ethics com-
mittee. The main characteristics of patients are summarised in
Table 1.
Reagents
Tuberculin (PPD) was from Statens Serum Institut (Copenha-
gen S, Denmark), cytomegalovirus (CMV) was from Cambrex
Bio Science (Emerailville, France), and Tetanus toxoid (TT)
and Candida (Cd) antigens were from Sanofi Diagnostics
Pasteur (Aulnay-sous-Bois, France). Toxoplasma gondii
(Toxo) was prepared from rough extract of tachyzoites (Francis
Derouin, Hôpital Saint Louis, Paris, France). Phytohemaggluti-
nin was from Murex Diagnostics (Paris).
Recombinant CFP-10 was cloned as histidine-tagged prod-
ucts as previously described [33,34] and purified with the use
of a Talon resin (Clontech, Broendbry, Denmark) in 8 M urea
followed by fractionation on a Hitrap Q HP column (GE
Healthcare, Little Chalfont, Buckinghamshire, UK, formerly
Amersham Biosciences) in 3 M urea. The fractions were ana-
lysed by use of silver-stained SDS-PAGE and western blotting
with an anti-histidine antibody (Clontech) and a polyclonal anti-
Escherichia coli antibody (Dako, Glostrup, Denmark) to detect
contaminants. Fractions more than 99% pure were pooled
and dialysed with 25 mM Hepes (pH 8.5). PPD and CFP-10
were used at 1 µg/ml and 0.5 µg/ml, respectively. For in vitro
assays with Ifx, Ada, or Eta, human immunoglobulin G1-Kappa
purified from myeloma serum (Serotec, Sergy Saint-Christo-
phe, France) was used as a control.
Ex vivo and in vitro assays
Thymidine incorporation (studied at day 5 of culture) and
(PKH)-26 dilution assays (studied at day 7 of culture) were
performed as described [35,36]. The PKH-26 assay detects
CD4+ T lymphocyte proliferation at the single-cell level. Briefly,
patients' peripheral blood mononuclear cells (PBMCs) were
labeled with PKH-26, cultured in the presence of the antigen,
and tested by flow cytometry for PKH-26 labeling and for the
expression of CD3 and CD4. Each round of CD4+ T-cell pro-
liferation during culture leads to a half-decrease of PKH-26
labeling intensity. IFN release was studied after 18 hours of
culture of 2 × 105 cells per well by means of an enzyme-linked
Table 1
Characteristics of patients
Group I Group II Group III Group IV
n 37 31 21 24
Age (median, IQR) 43 (31–59) 52 (42–56) 65 (37–72) 60 (50–72)
Gender (male/female) 19/18 13/18 11/10 14/10
IMID* (RA/SA/CD) 13/12/12 16/13/2 0 0
TNF antagonists*
RA (Ifx/Ada/Eta) 11 (0/1/10) 12 (3/2/7) 0 0
SA (Ifx/Ada/Eta) 9 (2/1/6) 13 (8/1/4)
CD (Ifx/Ada/Eta) 11 (11/0/0) 0 (0/0/0)
Previous anti-TB treatment 0 2 0 20
Associated immunosuppressors 
(MTX/AZA/CT)
17/6/18 14/1/11 0 0
TST (≥10 mm) 0/37 31/31 0/21 24/24
*A few patients were studied at inclusion but not at week 14. Ada, adalimumab; AZA, azathioprine; CD, Crohn's disease; CT, corticosteroids (≤10 
mg/day); Eta, etanercept; Ifx, infliximab; IMID, immune-mediated inflammatory disease; IQR, interquartile range; MTX, methotrexate; RA, 
rheumatoid arthritis; SA, spondylarthropathy; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test.
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immunosorbent spot (ELISPOT) assay (Diaclone, Besançon,
France). CD4+ T lymphocyte depletion from PBMCs was per-
formed using Dynabeads® CD4 coated beads with anti-CD4
mAb (Dynal Biotech, Compiègne, France).
To assess the in vitro effects of TNF antagonists, we deter-
mined proliferation using thymidine incorporation assays.
These experiments were performed from the week-0 sample
and when allowed by PBMC recovery, and response to myco-
bacterial antigens was tested as a priority to other antigens.
Because the therapeutic range of residual serum concentra-
tion is between 1 and 10 µg/ml for the three drugs [2,37,38],
we used 10 µg/ml of Eta, Ada, and Ifx unless specified. Median
effective concentration (EC50) values were determined using
the WinNonlin Professional software (v3.1; Pharsight Corpo-
ration, Mountain View, CA, USA). Anti-interleukin (IL)-12
Figure 1
Responses to mycobacterial antigens in patients with or without an immune-mediated inflammatory disease (IMID)i i i fl i  I I ). The response to purified protein 
derivative (PPD) (a) and to culture filtrate protein (CFP)-10 (b) was analysed using the thymidine incorporation, (PKH)-26 dilution, and enzyme-
linked immunosorbent spot (ELISPOT) assays in patients with (groups I, dotted boxes and II, gray shaded boxes) or without (groups III, diagonally 
lined boxes and IV, horizontally lined boxes) an IMID, and with previous or latent tuberculosis (groups II and IV) or without (groups I and III). Group I 
included 13, 12, and 12 patients with rheumatoid arthritis (RA), sponlylarthropathy (SA), and Crohn's disease (CD), respectively. Group II included 
16, 13, and 2 patients with RA, SA, and CD, respectively. Twenty-one and 24 patients were studied in groups III and IV, respectively. The thymidine 
incorporation, (PKH)-26 dilution, and enzyme-linked immunosorbent spot (ELISPOT) assays were performed, with results expressed (mean ± stand-
ard error of the mean) as stimulation index (SI), fraction of proliferating cells (percentage), and number of interferon (IFN)-γ-producing cells per 106 
cells. Comparisons for each assay were between groups I and II and between groups III and IV (*p < 0.05 and **p < 0.005, Mann-Whitney U test).
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Figure 2
CD4+ T lymphocytes are the main cells responding to Mycobacterium tuberculosis antigenst  i  l  r s n in  to ycobacteriu  tuberculosis antigens. (a) Proliferative responses ([PKH]-26 assay) to purified 
protein derivative (PPD) and to culture filtrate protein (CFP)-10 are shown for two individuals, one without (no tuberculosis [TB]) and the other with 
a previous or latent TB. Dot plots are gated on CD3+ cells and analyse the fluorescence intensity for both CD4 and PKH-26. Proliferating cells are 
PKH-26low. The percentage of CD3+ cells in each quadrant is shown. (b) The release of interferon (IFN)-γ in response to PPD, CFP-10, or phytohe-
magglutinin (PHA) was tested using the enzyme-linked immunosorbent spot assay, evaluating the response of either unfractionated peripheral blood 
mononuclear cells (PBMCs) (left) or PBMCs depleted of CD4+ T lymphocytes (right). Results are from two individuals with previous or latent TB and 
are expressed as the number of IFN-γ-releasing cells per million cells.
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blocking antibody and its isotype control were used at 10 µg/
ml (R&D Systems, Lille, France). Cultures were performed in
the presence of 10% heat-decomplemented human AB-
serum. We verified that no complement activity remained after
heat inactivation.
Analysis of mTNF expression on T cells was performed by flow
cytometry with anti-CD3-phycoerythrin, anti-CD4-phycoeryth-
rin-cyanin-5.1 (Beckman Coulter, Villepinte, France), and anti-
human extracellular TNF-fluorescein-isothiocyanate (clone
6,401) (R&D Systems) mAbs.
Statistical analysis
Results were analysed with use of the non-parametric Mann-
Whitney U test for descriptive evaluations between patients
with or without TB. The Wilcoxon test was used for compari-
sons of paired values. Bonferroni corrections were performed
for multiple comparisons. A p < 0.05 was considered as sig-
nificant.
Results
Immune responses to mycobacterial antigens in patients 
with IMID before treatment with TNF antagonists
The response to PPD and to the TB-specific antigen CFP-10
was compared between patients with or without an IMID.
Three different assays were performed. Two of them tested
lymphocyte proliferation, analyzing either PBMC (thymidine
incorporation assay) or CD4+ T lymphocytes (PKH-26 dilution
assay). The third assay evaluated the number of IFN-γ-releas-
ing cells (ELISPOT assay). The response against PPD was
stronger in patients with a previous TB (p < 0.05 for compari-
sons between groups I and II, and between groups III and IV)
(Figure 1a). However, when patients with and without an IMID
were compared (regardless of the assay used), the intensity of
the PPD-induced response was in the same range (group I
versus II and group III versus IV, respectively, p > 0.05 for all
comparisons). A response to CFP-10 was observed only in
patients with a previous TB, regardless of the presence of an
IMID (p < 0.005) (Figure 1b).
When considering RA and SA independently, similar conclu-
sions were reached: responses induced by PPD and CFP-10
were in the same range as those of controls, for the three
assays (Figure 1a,b). The limited number of patients with CD
and previous TB (n = 2) precluded definitive conclusion
regarding this group. Thus, neither the underlying IMID nor its
treatment affected the ex vivo intensity of lymphocyte
responses to mycobacterial antigens.
Proliferation in response to PPD and to CFP-10 was mostly
restricted to CD4+ T lymphocytes, with only a few CD4- T lym-
phocytes proliferating when stimulated by these antigens (Fig-
ure 2a). CD4-depletion experiments also showed that CD4+
cells were the major IFN-γ-releasing cells in the ELISPOT
assay (Figure 2b). Analysis of proliferative responses to myco-
bacterial-unrelated antigens (Cd, CMV, TT, and Toxo) also
Figure 3
Proliferative responses to recall antigens in patients with immune-mediated inflammatory diseasei i i - i  i fl t r  i . The proliferative response to purified protein deriv-
ative (PPD), Candida (Cd), cytomegalovirus (CMV), Tetanus toxoid (TT), and Toxoplasma gondii (Toxo) was evaluated using the thymidine incorpo-
ration assay. Patients were from group I (dotted boxes) (n = 28) and from group II (gray shaded boxes) (n = 26), before TNF (tumour necrosis factor) 
antagonist administration, and from group III (diagonally lined boxes) (n = 20) and from group IV (horizontally lined boxes) (n = 14). Results are 
expressed as stimulation indices (SIs) (mean ± standard error of the mean). P > 0.05 for all comparisons between groups I and III and between 
groups II and IV, Mann-Whitney U test.
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revealed no significant difference between patients with or
without an IMID (Figure 3).
Evolution of anti-mycobacterial immune responses in 
patients treated with TNF antagonists
The intensity of the immune response against PPD and CFP-
10 was determined in patients from groups I and II at inclusion
and 14 weeks after initiation of TNF antagonist treatment.
Treatment had no effect on the intensity of the proliferative
response, regardless of the test used or of the mycobacterial
antigen tested (p > 0.05 for all comparisons). In contrast, the
number of IFN-γ-releasing cells in response to PPD (for groups
I and II) and to CFP-10 (for group II) significantly decreased
with treatment (Figure 4). This decrease was independent of
an associated anti-TB treatment. The anti-PPD response
indeed decreased in group I patients, who required no anti-TB
treatment before administration of TNF antagonists. The anti-
PPD and anti-CFP-10 responses also decreased in the two
patients from group II previously treated for TB and thus need-
ing no additional anti-TB treatment. In these two patients, the
number of IFN-γ-releasing cells decreased by an average 89%
and 72% for PPD and CFP-10, respectively. TNF antagonists
decreased the number of IFN-γ-releasing cells to the same
extent in patients with RA or SA (data not shown). These find-
ings indicate that in vivo administration of TNF antagonists
decreases the number of anti-TB CD4+ T lymphocytes imme-
diately releasing IFN-γ in response to mycobacterial antigens,
whereas this treatment does not affect proliferative responses
to the same antigens.
Figure 4
Effect of tumour necrosis factor (TNF) antagonist treatment on anti-mycobacterial responsesi f  ( ) t i t treat ent on anti- ycobacterial responses. The effect of 14-week treatment with a TNF antagonist 
on the immune response against purified protein derivative (PPD) was determined in patients without a previous or latent tuberculosis group I (a), 
and in patients with a previous or latent tuberculosis group II (b). The effect of 14-week treatment with a TNF antagonist on the immune response 
against culture filtrate protein (CFP)-10 was determined in patients with a previous or latent tuberculosis group II (c). The thymidine incorporation, 
(PKH)-26 dilution, and enzyme-linked immunosorbent spot (ELISPOT) assays were performed, with results expressed (mean ± standard error of the 
mean) as stimulation indice (SI), fraction of proliferating cells (percentage), and number of interferon (IFN)-γ-producing cells per 106 cells. n = 31 in 
(a) and n = 25 in (b) and (c). *p < 0.01, **p < 0.005 for comparisons between week 14 and week 0 (Wilcoxon test).
Arthritis Research & Therapy    Vol 8 No 4    Hamdi et al.
Page 8 of 15
(page number not for citation purposes)
We compared Ifx and Eta for their effect on IFN-γ release;
because of their limited numbers, patients treated with Ada
could not be tested for this. Treatments with Ifx or Eta
decreased the number of IFN-γ-releasing cells in response to
both PPD (in groups I and II patients) and CFP-10 (in group II
patients) (Figure 5).
In vitro effects of TNF antagonists on the activation of 
anti-mycobacterial T lymphocytes
The above experiments analysed the impact of TNF antagonist
treatment on the in vivo persistence of anti-mycobacterial
CD4+ T lymphocytes. Because no patients suffered from
active TB, these lymphocytes were presumably resting mem-
ory T lymphocytes at the moment of blood collection. To ana-
lyse the effect of TNF antagonists on the activation of anti-
mycobacterial CD4+ T lymphocytes, we performed in vitro
studies in which TNF antagonists were added to PBMC cul-
tures stimulated with mycobacterial antigens. All patients
tested had a previous or latent TB, and none of them received
TNF antagonists when blood was collected. Ifx and Ada at 10µg/ml inhibited PPD-induced proliferation, both in thymidine
incorporation and in PKH-26 dilution assays. The responses in
the presence of Eta (10 µg/ml) did not significantly differ from
those of controls (Figure 6a,b). Similar findings were observed
when testing CFP-10-induced proliferation (data not shown).
However, increasing the dose of Eta above 10 µg/ml inhibited
the anti-PPD response (Figure 6c). The EC50 (standard error
of the mean) values for Ifx, Ada, and Eta were 10.7 (2.0) µg/
ml, 7.1 (2.0) µg/ml, and 21.6 (9.0) µg/ml, respectively. Similar
findings were observed for the anti-CFP-10 response (data
not shown). Therefore, all TNF antagonists added in vitro
inhibited the proliferative response of activated anti-mycobac-
terial CD4+ T lymphocytes, but the concentration of Eta had to
be two to three times higher than that of Ifx or Ada to obtain
this effect. To address whether the effect of TNF antagonists
(10 µg/ml each) on T-lymphocyte activation was restricted to
the anti-PPD response, we tested their effect on the prolifera-
tive response against Cd, CMV, and TT. Ifx and Ada signifi-
Figure 5
Effect of infliximab (Ifx) and etanercept (Eta) treatment on anti-mycobacterial responsesi i . The effect of 14-week treatment with Ifx or with Eta on inter-
feron (IFN)-γ release induced by purified protein derivative (PPD) in patients from group I, (a) or in patients from group II (b). The effect of 14-week 
treatment with Ifx or with Eta on interferon (IFN)-γ release induced by culture filtrate protein (CFP)-10 was determined in patients from group II (c). 
Results are expressed (mean ± standard error of the mean) as number of interferon (IFN)-γ-producing cells per 106 cells. n = 13 and 16 for Ifx and 
Eta respectively in (a). n = 11 for both Ifx and Eta in (b) and (c). *p < 0.01 for comparisons between week 0 and week 14 (Wilcoxon test).
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cantly inhibited the response to all antigens. Eta strongly
inhibited the response to CMV, whereas it had no significant
effect on the response against the other antigens (Figure 7).
In vitro effects of TNF antagonists on mTNF expression 
by CD4+ T lymphocytes
To begin to determine the mechanism of action of TNF antag-
onists on T-lymphocyte activation, we quantified mTNF expres-
sion by CD4+ T lymphocytes in cultures stimulated with
mycobacterial antigens. PPD stimulation increased the frac-
tion of mTNF-expressing CD4+ T lymphocytes. CFP-10 stimu-
lation also increased this expression, although to a lesser
extent. The addition at the initiation of culture of either Ifx or
Ada (10 µg/ml) decreased the fraction of mTNF-expressing
CD4+ T lymphocytes (Figure 8a). This effect persisted when
Ifx/Ada addition was delayed up to day 5 of culture (that is, 24
hours before assessing mTNF expression on CD4+ T lym-
phocytes) (Figure 8b,c). Eta had no effect on mTNF expres-
sion, regardless of the moment of its addition (Figure 8a–c).
To analyse the mechanism involved in the downregulation of
mTNF expression, we stimulated PBMCs with PPD for 5 days.
Cells were stained with an anti-TNF mAb (clone 6401) before
and after incubated with Ifx or a control antibody at either 4°C
or 37°C for 4 hours. With Ifx, mTNF expression by CD4+ T lym-
phocytes decreased at 37°C but not at 4°C (Figure 9). Results
at 4°C showed an absence of competition between Ifx and the
anti-TNF mAb (clone 6,401) used to stain the cells. Thus, the
decreased expression of mTNF reported in Figure 8 cannot be
explained by competition during labeling. In contrast, results at
37°C showed that Ifx induces a rapid disappearance of mTNF
from CD4+ T lymphocytes, involving an active process that
could be either mTNF internalization or shedding.
Delayed addition of TNF antagonists inhibits anti-
mycobacterial proliferative responses
The effect of TNF antagonists on mTNF expression suggested
that they directly acted on activated T lymphocytes. To further
support such a hypothesis, we determined whether delaying
Figure 6
In vitro effect of tumour necrosis factor (TNF) antagonists on anti-mycobacterial proliferative response. In patients with previous or latent TB, lym-
phocyte proliferation was determined using the thymidine incorporation assay after 5 days of activation with purified protein derivative (PPD) in the 
presence of 10 µg/ml of a control antibody (-) or of infliximab (Ifx), adalimumab (Ada), or etanercept (Eta) (a). In patients with previous or latent TB, 
lymphocyte proliferation was determined using the thymidine incorporation assay after 5 days of activation with culture filtrate protein (CFP)-10 in 
the presence of 10 µg/ml of a control antibody (-) or of infliximab (Ifx), adalimumab (Ada), or etanercept (Eta) (b). Twelve patients were tested: four 
from group II, before TNF antagonist administration, and eight from group IV, with similar findings in both cases. (c) Graded concentrations of TNF 
antagonists were added to PPD-stimulated cells (n = 9). Results are expressed as stimulation indices SIs (mean ± standard error of the mean 
(SEM). *p < 0.05 for paired comparison between Ifx, Ada, or Eta and the control antibody (Wilcoxon test with Bonferroni corrections).
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the addition of TNF antagonists up to day 5 of cultures still
inhibited lymphocyte proliferation induced by PPD. Delaying
the addition of Ifx or Ada (10 µg/ml) decreased the magnitude
of inhibition, but the inhibition persisted. Eta (10 µg/ml) had no
significant effect (Figure 10). Similar findings were observed
for the response to CFP-10 (data not shown).
Addition of a neutralizing anti-IL-12 mAb at the initiation of cul-
tures inhibited the proliferation induced by PPD or CFP-10,
showing the contribution of IL-12 (a product of antigen-pre-
senting cells) in anti-mycobacterial proliferative responses.
This effect was lost when the anti-IL-12 mAb was added later,
either on day 2 or on day 5 (Figure 10 and data not shown). IL-
12 was thus not required during the last days of lymphocyte
proliferation. Therefore, Ifx and Ada affected a late event in lym-
phoproliferative responses, independently of IL-12, and this is
consistent with a direct effect of TNF antagonists on T lym-
phocytes activated by mycobacterial antigens.
Discussion
In this work, we studied the impact of IMIDs and their classical
treatment on anti-Mtb immune responses and we evaluated
the effect of TNF antagonists on such responses, using the
recently identified Mtb-specific antigens CFP-10 and ESAT-6
and newly developed immunological assays. Because results
with CFP-10 and ESAT-6 were identical in all instances, only
findings with CFP-10 are reported in the present work. We
studied the impact of treatment with TNF antagonists on the
ex vivo response of circulating anti-Mtb T lymphocytes and the
effect of TNF antagonists added in vitro during activation of
these cells by mycobacterial antigens.
Assays based on the quantification of IFN-γ-releasing cells
allow diagnosis of active TB [31], recent primary infection
[30,32], and latent TB [28]. Our findings extend these previ-
ous reports in several aspects. We show that, in addition to
IFN-γ release, proliferative responses induced by Mtb-specific
antigens are witnesses of a prior contact with Mtb. We also
show that in patients with IMIDs and before initiation of treat-
ment with TNF antagonists, ex vivo evaluation of anti-Mtb
immune responses accurately reflects previous or latent TB
because our biological findings correlate well with the current
investigation of previous or latent TB. Additional studies are in
progress to determine which combination of mycobacterial
antigens and assays is optimal to diagnose latent TB and
whether it compares favorably with the TST.
Our results also show that the intensity of anti-Mtb immune
responses was preserved in patients with IMIDs as compared
with patients without. This was observed regardless of the
IMID considered, suggesting that neither an IMID nor its clas-
sical treatment significantly affects anti-mycobacterial CD4+ T
lymphocytes. Independently of TNF antagonist treatments,
there are controversies concerning the impact of IMID on anti-
mycobacterial immune responses. Berg et al. showed a
decreased response to PPD in patients with RA [39]. These
authors measured IFN-γ production by enzyme-linked immuno-
sorbent assay 7 days after in vitro stimulation of PBMCs, an
assay clearly different from those we used (proliferation and
immediate IFN-γ release tested by ELISPOT). Likewise, a
decreased intensity of TST in patients with RA has been noted
[40], but this finding was not confirmed in two other recent
studies [41,42].
TNF antagonists increase the incidence and the severity of TB.
It was thus of interest to demonstrate that TNF antagonists act
in vivo on anti-TB immune cells and to define the type of
immune response targeted by these agents. Proliferation in
response to mycobacterial antigens remained unaffected 14
weeks after initiation of treatment with TNF antagonists. This
negative finding is significant because in patients with latent
TB and receiving no anti-TB treatment, reactivation of TB
peaks 12 weeks after initiation of Ifx treatment [11]. In contrast
to the preservation of proliferative responses, immediate
release of IFN-γ was affected by the administration of TNF
antagonists. The number of lymphocytes releasing IFN-γ within
18 hours after challenge with mycobacterial antigens signifi-
cantly decreased 14 weeks after initiation of treatment, as
compared with pre-treatment values. In most patients with pre-
vious or latent TB (group II patients), an anti-TB treatment was
associated with TNF antagonists, raising the hypothesis that
Figure 7
In vitro effect of tumour necrosis factor antagonists on proliferative responses to recall antigens
responses to recall antigens. The effect of infliximab (Ifx), adalimumab 
(Ada), and etanercept (Eta) (10 µg/ml) on the proliferation of lym-
phocytes was determined using the thymidine incorporation assay after 
5 days of activation with purified protein derivative (PPD), Candida 
(Cd), cytomegalovirus (CMV), or Tetanus toxoid (TT). Five patients (3 
from group III and 2 from group IV) were tested. Results (mean ± stand-
ard error of the mean) are expressed as percentage of controls, corre-
sponding to cells cultured with a control antibody. *p < 0.05 and **p < 
0.01 as compared with controls (Wilcoxon test with Bonferroni correc-
tions).
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anti-TB treatment rather than TNF antagonist treatment
decreased the number of IFN-γ-releasing lymphocytes. In
patients with active TB, anti-TB treatment is indeed associated
with a rapid decline of the anti-TB immune response, as
assessed by ELISPOT [28]. In this condition, the ELISPOT
assay evaluates not only resting memory cells, but also T lym-
phocytes recently activated in vivo by TB antigens. Such acti-
vated lymphocytes presumably vanish while TB replication
stops. In patients with latent TB, it is unknown whether the
anti-TB treatment affects the number of IFN-γ-releasing cells.
Although we cannot rule out a contribution of anti-TB treat-
ment in the decrease of IFN-γ-releasing cells we observed in
patients from group II, several arguments indicate that treat-
ment with TNF antagonists itself largely explains this decline.
First, the two patients from group II who did not receive any
anti-TB treatment did not differ from the others in terms of evo-
lution of the anti-Mtb immune response. Second, IFN-γ release
in response to PPD in group I patients (who received no anti-
TB treatment) also decreased during treatment with TNF
antagonists.
Circulating CD4+ T-lymphocyte numbers remain unaffected in
patients treated with TNF antagonists [43,44]. We add func-
tional findings to these previous studies. The preservation of
proliferative responses we observed is consistent with the
preservation of circulating CD4+ T-lymphocyte numbers. How-
ever, the decline of immediate IFN-γ release shows that treat-
ment with TNF antagonists does not affect all aspects of the
anti-mycobacterial immune response to the same extent. Mem-
ory T lymphocytes have been subdivided into effector/memory
Figure 8
In vitro effect of tumour necrosis factor (TNF) antagonists on membrane-bound TNF (mTNF) expression. In patients previously infected with TB 
(either from group II or IV), peripheral blood mononuclear cells were cultured alone (black shaded boxes), with purified protein derivative (PPD) 
(diagonally lined boxes), or with culture filtrate protein (CFP)-10 (horizontally lined boxes), and with infliximab (Ifx), adalimumab (Ada), etanercept 
(Eta), or a control antibody (-) (10 µg/ml each). (a) The TNF antagonist was added at the initiation of the culture, and mTNF expression on CD4+ T 
lymphocytes was determined on day 5 (n = 10). (b) The TNF antagonist was added on day 5 of culture, and mTNF expression on CD4+ T lym-
phocytes was determined 24 hours later (n = 7). Results (mean ± standard error of the mean) are expressed as the fraction of mTNF+ cells among 
CD4+ T lymphocytes. Paired comparisons were performed. *p < 0.05 (Wilcoxon test with Bonferroni corrections) for comparisons between cultures 
with Ifx, Ada, or Eta and cultures with the control antibody. (c) Results from a typical patient in the same conditions as in (b).
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(TEM) and central/memory (TCM) subpopulations. Immediate
release of cytokines is typical of TEM, which proliferate poorly
in response to antigens. In contrast, proliferation is a hallmark
of TCM (reviewed in [40]). This suggests that TNF antagonists
affect anti-mycobacterial CD4+ TEM while sparing TCM. Expres-
sion of chemokine receptors also distinguishes TEM from TCM
(CCR7 and CD62L) [45]. However, lack of defined combina-
tions of Mtb peptides and HLA (human lymphocyte antigen)
class II tetramers makes difficult the analysis of chemokine
receptors on Mtb-specific CD4+ T lymphocytes.
The impaired IFN-γ release in patients treated with TNF antag-
onists indicates that ELISPOT assays should not be used to
diagnose previous or latent TB in patients on treatment with
TNF antagonists, whereas proliferative assays appear more
reliable. Recently approved commercial assays for the in vitro
detection of anti-TB immunity are based on IFN-γ release and
thus, if they are used, should be performed before beginning
anti-TNF. Interestingly, Ifx and Eta treatments decreased to the
same extent the number of IFN-γ-releasing cells in response to
mycobacterial antigens. This possibly contributes to the
increased risk of TB infection in patients treated with either Ifx
or Eta.
Ex vivo studies of anti-mycobacterial immune responses in
patients treated with TNF antagonists are useful for evaluating
the effect of these agents on circulating resting memory T lym-
phocytes, but they provide no clue for understanding their
effect on lymphocytes recently activated by Mtb antigens. To
address this issue, we determined whether the in vitro addition
of TNF antagonists influenced anti-mycobacterial immune
response. The results markedly differed from those evaluating
the in vivo effect of TNF antagonists. In vitro addition of TNF
antagonists resulted in a decreased proliferation in response
to mycobacterial antigens. It also prevented the upregulation
of mTNF expression by CD4+ T lymphocytes, another marker
of activation induced by mycobacterial antigens. This shows
that TNF antagonists either prevent activation of anti-myco-
bacterial memory T lymphocytes or directly affect activated
cells. An effect of TNF antagonists on antigen-presenting cells
could account for the first hypothesis. Both Ifx and Eta may
induce apoptosis of monocytes/macrophages [46], which are
involved in antigen presentation to T lymphocytes and IL-12-
mediated activation of these cells. Elimination of monocytes/
macrophages may participate in the inhibition of anti-myco-
bacterial responses. Although we cannot rule out this hypoth-
esis, two findings supported a direct action of TNF antagonists
on activated anti-mycobacterial T lymphocytes. First, delaying
the addition of the TNF antagonist up to 24 to 48 hours before
the end of the culture was sufficient to decrease both prolifer-
ation and the fraction of mTNF-expressing cells. Second, Ifx
induced a rapid (within 4 hours) and active disappearance of
mTNF from the surface of CD4+ T lymphocytes, possibly
Figure 9
Expression of membrane-bound tumour necrosis factor (mTNF) after 4 hou s of i cubation with infliximab (Ifx)
hours of incubation with infliximab (Ifx). Cells stimulated for 6 days with 
purified protein derivative were incubated with Ifx (10 µg/ml) or a con-
trol monoclonal antibody at 4°C or at 37°C for 4 hours. Expression of 
mTNF on CD4+ T lymphocytes was then determined. (a) Results are 
expressed as mean fluorescence intensity (MFI) ± standard error of the 
mean from three experiments. (b) One of these experiments is shown.
Figure 10
Delayed effect of tumour necrosis factor antagonists on lymphocyte proliferation
proliferation. Infliximab (Ifx), adalimumab (Ada), etanercept (Eta), or an 
anti-interleukine (IL)-12 monoclonal antibody (mAb) was added either 
at the initiation of culture or on day 2 or 5 to peripheral blood mononu-
clear cells stimulated with purified protein derivative. Thymidine incor-
poration was determined on day 7. Results (mean ± standard error of 
the mean) are expressed as the proportion of controls (performed in the 
presence of a control antibody). *p < 0.05 and **p < 0.01. n = 10 for 
Ifx, Ada, and Eta, and n = 3 for the anti-IL-12 mAb.
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involving internalization or shedding of mTNF. Regardless of
the mechanism(s) involved, a decreased mTNF expression by
activated anti-mycobacterial CD4+ T lymphocytes may signifi-
cantly alter their helper function, considering the role of mTNF
on anti-mycobacterial immune responses [19]. In cultures per-
formed with Ifx, apoptosis of activated CD4+ T lymphocytes,
expressing mTNF, could be an additional mechanism of inhibi-
tion of anti-mycobacterial immune response. This apoptosis
could occur through a direct effect of Ifx on either mTNF-
expressing cells [47,48] or antibody-dependent cell cytotoxic-
ity. Complement-mediated killing of mTNF-expressing cells is
excluded in our experiments, performed in complement-free
conditions.
The three TNF antagonists, when added in vitro, were not
equal in their ability to inhibit the responses induced by myco-
bacterial antigens. When tested at the 10 µg/ml concentra-
tion, inhibition was observed with Ifx and Ada but not with Eta.
This observation was not due to an intrinsic inability of Eta to
block anti-mycobacterial immune responses, because increas-
ing its concentration up to 40 µg/ml allowed such an inhibi-
tion. However, EC50 studies indicated that Eta is two to three
times less efficient than Ifx and Ada in inhibiting in vitro anti-
mycobacterial responses. With the exception of CMV anti-
gens, Eta is also less efficient than Ifx and Ada to inhibit the in
vitro response to recall antigens other than mycobacterial anti-
gens. Although Eta fully neutralises soluble TNF, it is not as
efficient as anti-TNF mAbs for binding mTNF-expressed by
monocytes/macrophages and Jurkat T lymphocytes
[16,47,48]. Because mTNF expression is upregulated on
CD4+ T lymphocytes activated by mycobacterial antigens, the
anti-TNF antibodies may alter the function of activated anti-
Mtb T lymphocytes more than Eta. These alterations may
occur in vivo in patients with TB reactivation given that they
were observed in vitro at concentrations of TNF antagonists
(1–10 µg/ml) corresponding to their therapeutic range [2,38].
Therefore, TB reactivation may stimulate anti-Mtb T lym-
phocytes and expose them to inhibition or deletion by anti-TNF
mAbs. This could explain why TB reactivations in patients
treated with TNF antagonists are so severe and disseminated,
with few granulomas in involved tissues, and why they might
be more frequent with Ifx than with Eta.
Conclusion
This work shows that TNF antagonists have a dual effect on
anti-mycobacterial CD4+ T lymphocytes. Their in vivo adminis-
tration results in a decline of subpopulations of anti-mycobac-
terial memory CD4+ T lymphocytes, especially those rapidly
releasing IFN-γ upon challenge with mycobacterial antigens.
All TNF antagonists tested appear as efficient to induce this
decline. In contrast, anti-TNF mAbs are more efficient than Eta
in inhibiting the in vitro activation of CD4+ T lymphocytes by
mycobacterial antigens, presumably reflecting their higher
potency in interacting with mTNF expressed by activated
CD4+ T lymphocytes. Such a dual effect may explain the
increased incidence of TB in patients treated with TNF antag-
onists as well as possible differences between TNF antago-
nists for the incidence and the clinical presentation of TB
reactivation.
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